SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001640455-22-000100
Filing Date
2022-11-10
Accepted
2022-11-10 07:17:16
Documents
14
Period of Report
2022-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K jnce-20221110.htm   iXBRL 8-K 39907
2 EX-99.1 jnce09302022exhibit991.htm EX-99.1 72280
6 jounceheadera.gif GRAPHIC 8639
  Complete submission text file 0001640455-22-000100.txt   276006

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT jnce-20221110.xsd EX-101.SCH 1903
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT jnce-20221110_lab.xml EX-101.LAB 24831
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT jnce-20221110_pre.xml EX-101.PRE 13047
8 EXTRACTED XBRL INSTANCE DOCUMENT jnce-20221110_htm.xml XML 11710
Mailing Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 857-259-3840
Jounce Therapeutics, Inc. (Filer) CIK: 0001640455 (see all company filings)

IRS No.: 454870634 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37998 | Film No.: 221374925
SIC: 2836 Biological Products, (No Diagnostic Substances)